Lai Kai Medicine-B (02105.HK): Conduct on-market share repurchases and senior management share acquisition plans in accordance with the repurchase authorization.

Zhtng Cijng APP news, Lai Kai Pharmaceutical-B (02105.HK) issued an announcement to demonstrate confidence in the company's business prospects and create value for shareholders. The company's board of directors approved on July 1, 2026, based on the shareholders' authorization to repurchase shares at the annual general meeting held on June 5, 2026, and any general authorization to repurchase shares approved by shareholders at subsequent general meetings (repurchase authorization), to repurchase the company's common stock (shares) in the open market. At the same time, the board learned that Dr. Lu Xiangyang, chairman of the board of directors, together with several senior management members of the company, plans to increase their equity in the company by purchasing the company's shares in the open market. The company and senior management will conduct on-market share repurchases and shareholding plans in accordance with the company's articles of association, the rules of the Hong Kong Stock Exchange, and other applicable laws and regulations. The on-market share repurchase plan will be funded by the company's existing available cash resources. The shares repurchased by the company will be cancelled afterwards. The senior management's shareholding plan will be funded by their personal financial resources. The coordinated actions reflect the board of directors and management's confidence in the company's business prospects and future development, and will be beneficial for the company and create value for shareholders. The total amount for the company's on-market share repurchases and senior management's share increases is up to HK$56 million.